Axon Enterprise (NASDAQ:AXON) Price Target Raised to $895.00

Axon Enterprise (NASDAQ:AXON - Get Free Report) had its target price upped by analysts at Bank of America from $750.00 to $895.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the biotechnology company's stock. Bank of America's price objective points to a potential upside of 13.53% from the stock's previous close.

AXON has been the topic of a number of other reports. JMP Securities reiterated an "outperform" rating on shares of Axon Enterprise in a report on Tuesday, February 4th. Craig Hallum lowered shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a report on Monday, March 10th. Northcoast Research lowered shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a report on Wednesday, February 19th. The Goldman Sachs Group increased their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research report on Wednesday, May 14th. Finally, Needham & Company LLC increased their target price on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $699.55.

Axon Enterprise Trading Up 1.1%

Shares of AXON stock traded up $8.36 during trading hours on Wednesday, hitting $788.36. The company had a trading volume of 681,854 shares, compared to its average volume of 734,273. The company's fifty day moving average is $633.63 and its 200 day moving average is $613.89. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. Axon Enterprise has a fifty-two week low of $276.92 and a fifty-two week high of $793.24. The stock has a market capitalization of $61.37 billion, a PE ratio of 203.71, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.34 by $0.07. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The firm had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. During the same period in the prior year, the business posted $1.15 EPS. The business's revenue for the quarter was up 31.3% compared to the same quarter last year. Research analysts expect that Axon Enterprise will post 5.8 earnings per share for the current fiscal year.

Insider Activity at Axon Enterprise

In related news, Director Jeri Williams sold 307 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $552.72, for a total value of $169,685.04. Following the completion of the sale, the director now directly owns 1,627 shares in the company, valued at approximately $899,275.44. The trade was a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael Garnreiter sold 87 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $760.00, for a total transaction of $66,120.00. Following the completion of the sale, the director now owns 24,653 shares of the company's stock, valued at approximately $18,736,280. The trade was a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,969 shares of company stock worth $29,909,594 over the last 90 days. Company insiders own 4.40% of the company's stock.

Institutional Investors Weigh In On Axon Enterprise

Institutional investors have recently bought and sold shares of the stock. Fourth Dimension Wealth LLC purchased a new stake in Axon Enterprise in the fourth quarter valued at approximately $30,000. TCTC Holdings LLC grew its holdings in Axon Enterprise by 75.0% in the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 24 shares during the period. Bartlett & CO. Wealth Management LLC grew its holdings in Axon Enterprise by 132.0% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock valued at $31,000 after purchasing an additional 33 shares during the period. Catalyst Capital Advisors LLC purchased a new stake in Axon Enterprise in the first quarter valued at approximately $32,000. Finally, Banque Transatlantique SA purchased a new stake in Axon Enterprise during the first quarter worth approximately $31,000. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.